Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Mobia Medical, a medical device company specializing in stroke recovery technologies, reported a robust second quarter 2026 with $13.5 million revenue, up 102% year-over-year, and gross margin of 83.2%. The company completed its IPO, raising $134 million in net proceeds, strengthening its cash position to $177.1 million. It also announced publicati…
Insight Molecular Diagnostics (IMDX) announced a virtual key opinion leader event featuring prominent experts to discuss the GraftAssure platform, which utilizes digital PCR technology to enable rapid and reliable donor-derived cell-free DNA testing for transplanted organ health monitoring. The GraftAssureDx test kit is currently under FDA review t…
Nasdaq announced its end-of-month short interest data as of July 31, 2026. The report shows a slight decrease in the total shares sold short in both the Nasdaq Global Market and Nasdaq Capital Market compared to the prior reporting period. The days to cover metric has modestly increased, indicating a slight change in market shorting trends.
Comscore has announced a comprehensive ROI Strategy aimed at transforming its business by realigning operations, optimizing organizational efficiency, and investing in future growth areas. The plan includes reducing annual costs by $20 to $25 million through restructuring and headcount reduction, simplifying operations, improving product developmen…
Factorial Energy Inc., a Nasdaq-listed company specializing in solid-state battery technology, announced its financial and business results for Q2 2026. The company highlighted its leadership in the development of scalable solid-state batteries for aerospace, energy storage, and mobility applications, supported by significant partnerships with majo…
Inuvo, Inc. reported its Q2 2026 financial results, highlighting a 19% year-over-year growth in Audience Modeling revenue driven by new client wins and increased investment from existing customers. However, total net revenue declined 67% due to an 80% decrease in Legacy Search revenue. The company took strategic steps to reduce costs associated wit…
High Roller Technologies reported its Q2 2026 financials, marked by a revenue decline due to strategic market exits and a focus on prediction markets. The company achieved significant regulatory milestones for its ROLR prediction platform, gaining approval as a member of the National Futures Association and planning a U.S. launch via Crypto.com der…
Firefly Aerospace has announced a two-year extension of its multi-launch agreement with Lockheed Martin to utilize the Alpha Block II rocket configuration for up to 25 launches through 2031. This upgrade enhances manufacturability, reliability, and responsiveness, allowing Firefly to meet high demand for dedicated launches in the 1,000 kg payload c…
Hour Loop, Inc., a U.S.-based online retailer, announced its second quarter 2026 financial results with net revenues increasing 25% year-over-year to $33.9 million. Despite higher revenues, net income slightly declined to $1.1 million from $1.2 million, reflecting margin pressures and increased costs. The company continues to invest in inventory an…
Mobile Infrastructure Corporation reported its second quarter 2026 financial results with same-location revenue growth of 5.6% year-over-year and contract parking volumes increasing approximately 12%. Despite a slight decrease in total revenue due to recent asset sales, same-location net operating income rose 12%. The company paid down $4.5 million…
SELLAS Life Sciences reported its Q2 2026 financial results, highlighting progress in its lead cancer drug candidates GPS and SLS009, both targeting acute myeloid leukemia (AML). The Phase 3 REGAL trial for GPS is nearing the critical 80th event for final analysis, potentially leading to FDA Biologics License Application submission. The Phase 2 tri…
H&R Block reported fiscal 2026 financial results showcasing a 5% revenue increase to $3.95 billion, a 21% rise in net income from continuing operations, and a 29% increase in earnings per share. The company returned $714 million to shareholders through dividends and share repurchases, raising its quarterly dividend by 10%. For fiscal 2027, it proje…
Mineralys Therapeutics announced its second quarter 2026 financial results, including a strengthened balance sheet following a $150 million public offering and a $100 million tranche drawn on a $500 million term loan. The company is on track for FDA's PDUFA target date of December 22, 2026, for lorundrostat, an aldosterone synthase inhibitor target…
Seer, Inc., a proteomics technology company, announced its second quarter 2026 financial results, reporting $3.1 million in revenue, a 23% decline year-over-year, driven by macroeconomic challenges and elongated sales cycles. Despite the revenue decline, gross margin remained solid at 49%, operating expenses and net loss decreased compared to the p…
Kyverna Therapeutics reported Q2 2026 financial results and significant clinical and regulatory progress for its lead CAR T-cell therapy candidate, miv-cel, targeting neurologic autoimmune diseases. The FDA granted RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis, highlighting promising clinical data. The company …
Inhibikase Therapeutics announced its Q2 2026 financial results, highlighting significant progress in its Phase 3 IMPROVE-PAH clinical trial for IKT-001, a novel oral treatment for Pulmonary Arterial Hypertension (PAH). The company secured regulatory approvals in 26 countries, initiated 43 clinical sites globally, and obtained Orphan Drug Designati…
Belite Bio announced FDA acceptance and Priority Review of its New Drug Application for tinlarebant, a novel oral therapy intended to treat Stargardt Disease Type 1 (STGD1), a rare inherited retinal disease. The NDA submission is supported by positive Phase 3 DRAGON trial results demonstrating a 35.7% reduction in atrophic retinal lesion growth rat…
Leonardo DRS demonstrated that its SGT STOUT M-SHORAD Mission Equipment Package can effectively defeat smaller Group 1-2 unmanned aerial systems through software updates without hardware changes, highlighting its modular and upgradeable architecture. This marks a significant advancement in scalable, modern air defense capabilities, emphasizing rapi…
Aquestive Therapeutics reported a Q2 2026 revenue increase driven by manufacturing and royalties and reaffirmed plans to resubmit its Anaphylm (dibutepinephrine) NDA to the FDA in Q3 2026 following successful human factors and pharmacokinetic studies. The company continues to advance its epinephrine AdrenaVerse platform, including AQST-108 for derm…
Maze Therapeutics announced its Q2 2026 financial results alongside clinical updates on its Phase 2 programs targeting APOL1-mediated kidney disease and phenylketonuria. Enrollment in multiple Phase 2 trials is progressing on schedule, with important data expected in late 2026 and 2027. The company holds a strong cash position of nearly $495 millio…
Erasca, Inc. announced encouraging updated clinical data for its ERAS-0015 candidate showing promising efficacy and tolerability in KRAS G12X pancreatic and lung cancers. The company raised $632 million in a recent upsized public offering to advance multiple registration-enabling trials and strengthen its balance sheet. Several key clinical milesto…
Xcel Brands, a media and consumer products company, announced it will report its Q2 2026 financial results on August 13, 2026, followed by an earnings call on August 14. The company focuses on branded apparel, accessories, and social commerce, owning several lifestyle brands and utilizing diverse sales channels including live streaming and interact…
Taysha Gene Therapies reported Q2 2026 financial results and corporate updates including completed dosing in its pivotal REVEAL and ASPIRE trials for TSHA-102 gene therapy targeting Rett syndrome. The therapy showed a favorable safety profile and promising longer-term functional benefits. The company has advanced commercial and manufacturing readin…
Lyft is not the global behemoth Uber is, but it has carved an economically viable niche in North America. With free cash flow of roughly $1.12B, a market cap near $7.0B and a P/E around 2.3, Lyft looks attractively priced for a mid-term tactical long. Trade plan: enter $17.55, stop $15.00, target $22.00 over a mid term (45 trading days).
Northrop Grumman has revealed Raid Hunter, a 50mm gun-centered air defense solution built to protect installations from cruise missiles, drone swarms and similar aerial threats. The system pairs Chain Gun mechanics, precision-guided 50mm rounds and a networked controller to deliver sustained, rapid fire from deep magazines. Designed for rapid movem…
